GALT GALECTIN THERAPEUTICS INC: institutional ownership and insider trading
111 funds reported holding $88.4M of GALECTIN THERAPEUTICS INC in their latest 13F filings; in Q2 2026 funds net bought $6.77M, with 19 new positions and 19 funds selling out; over the last 12 months insiders bought $6.03K and sold $5.89M on the open market.
GALT revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$9.11M, EPS -0.14
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.05M, EPS -0.08
- Quarter ended Dec 31, 2025: revenue n/a, net income −$5.50M, EPS -0.08
- Quarter ended Sep 30, 2025: revenue n/a, net income −$8.18M, EPS -0.13
Famous investors holding GALT
- Ken Griffin (Citadel Advisors): $2.50M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.48M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $201K, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $166K, 0.0% of the portfolio
Largest institutional holders of GALT
- BlackRock, Inc. (BLK) — $13.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $10.1M
- VANGUARD GROUP INC — $9.52M
- GEODE CAPITAL MANAGEMENT, LLC — $6.07M
- OSAIC HOLDINGS, INC. — $5.59M
- MARSHALL WACE, LLP — $3.86M
- GREAT POINT PARTNERS LLC — $3.71M
- Wealthspire Advisors, LLC — $3.35M
- STATE STREET CORP (STT, STT-PG) — $2.63M
- CITADEL ADVISORS LLC — $2.50M
Recent GALT insider trades
- Jul 14, 2026: Jamil Khurram sold 16,250 shares ($83.4K)
- Jun 29, 2026: Jamil Khurram sold 52,037 shares ($262K)
- Jun 29, 2026: Shlevin Harold H. sold 30,000 shares ($151K)
- Jun 23, 2026: Jamil Khurram sold 7,557 shares ($23.7K)
5%+ owners
- Richard E. Uihlein: 49.3% (Schedule 13D/A, filed Aug 4, 2026)